198 related articles for article (PubMed ID: 1577391)
41. High-dose famotidine in the maintenance treatment of refractory esophagitis: results of a "medium-term" open study.
Bianchi-Porro G; Pace F; Sangaletti O; Peracchia A; Bonavina L; Vigneri S; Termini R
Am J Gastroenterol; 1991 Nov; 86(11):1585-7. PubMed ID: 1951234
[TBL] [Abstract][Full Text] [Related]
42. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
[TBL] [Abstract][Full Text] [Related]
43. Gastroesophageal reflux disease in intellectually disabled individuals: leads for diagnosis and the effect of omeprazole therapy.
Bohmer CJ; Niezen-de Boer MC; Klinkenberg-Knol EC; Tuynman HA; Voskuil JH; Devillé WL; Meuwissen SG
Am J Gastroenterol; 1997 Sep; 92(9):1475-9. PubMed ID: 9317066
[TBL] [Abstract][Full Text] [Related]
44. Gastroesophageal reflux and histamine2 antagonists.
Bell SG
Neonatal Netw; 2003; 22(2):53-7. PubMed ID: 12696725
[No Abstract] [Full Text] [Related]
45. Efficacy of twice daily doses of 40 or 20 milligrams famotidine or 150 milligrams ranitidine for treatment of patients with moderate to severe erosive esophagitis. Famotidine Erosive Esophagitis Study Group.
Simon TJ; Berlin RG; Tipping R; Gilde L
Scand J Gastroenterol; 1993 May; 28(5):375-80. PubMed ID: 8511496
[TBL] [Abstract][Full Text] [Related]
46. Do H2 receptor antagonists have a therapeutic role in childhood?
Kelly DA
J Pediatr Gastroenterol Nutr; 1994 Oct; 19(3):270-6. PubMed ID: 7815256
[TBL] [Abstract][Full Text] [Related]
47. Acid suppression by famotidine 20 mg twice daily or 40 mg twice daily in preventing relapse of endoscopic recurrence of erosive esophagitis.
Simon TJ; Roberts WG; Berlin RG; Hayden LJ; Berman RS; Reagan JE
Clin Ther; 1995; 17(6):1147-56. PubMed ID: 8750406
[TBL] [Abstract][Full Text] [Related]
48. [Therapy of esophageal reflux disease].
Rösch W
Dtsch Med Wochenschr; 1982 Mar; 107(10):389-91. PubMed ID: 6277588
[No Abstract] [Full Text] [Related]
49. Efficacy of Lafutidine Versus Famotidine in Patients with Reflux Esophagitis: A Multi-Center, Randomized, Double-Blind, Non-inferiority Phase III Trial.
Kim EH; Lee YC; Chang YW; Park JJ; Chun HJ; Jung HY; Kim HS; Jeong HY; Seol SY; Han SW; Choi MG; Park SH; Lee OJ; Jung JT; Lee DH; Jung HC; Lee ST; Kim JG; Youn SJ; Kim HY; Lee SW
Dig Dis Sci; 2015 Jun; 60(6):1724-32. PubMed ID: 25532503
[TBL] [Abstract][Full Text] [Related]
50. Famotidine (20 mg) b.d. relieves gastrooesophageal reflux symptoms in patients without erosive oesophagitis. Famotidine/GERD Investigation Group.
Robinsen M; Decktor DL; Stone RC; Pevelery M; Barden P; Moyer R; Holt S; Root J; Hufnagel K; Humphries TJ
Aliment Pharmacol Ther; 1991 Dec; 5(6):631-43. PubMed ID: 1782306
[TBL] [Abstract][Full Text] [Related]
51. Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.
Langtry HD; Grant SM; Goa KL
Drugs; 1989 Oct; 38(4):551-90. PubMed ID: 2573505
[TBL] [Abstract][Full Text] [Related]
52. Comparative efficacy of cimetidine, famotidine, ranitidine, and mylanta in postoperative stress ulcers. Gastric pH control and ulcer prevention in patients undergoing coronary artery bypass graft surgery.
Lamothe PH; Rao E; Serra AJ; Castellano J; Woronick CL; McNicholas KW; Lemole GM
Gastroenterology; 1991 Jun; 100(6):1515-20. PubMed ID: 2019357
[TBL] [Abstract][Full Text] [Related]
53. Factors predicting relapse during maintenance treatment with famotidine in patients with healed reflux esophagitis. Dutch Esophagitis Study Group.
Wesdorp IC; Dekker W; Festen HP
Clin Ther; 1997; 19(5):1048-57. PubMed ID: 9385492
[TBL] [Abstract][Full Text] [Related]
54. Effect of cisapride and cimetidine on 24-hour intraesophageal pH monitoring in patients with gastroesophageal reflux disease.
Chojnacki J; Tkaczewski W; Wichan P; Grzegorczyk K; Klupińska G
Mater Med Pol; 1992; 24(3):196-8. PubMed ID: 1307654
[TBL] [Abstract][Full Text] [Related]
55. Comparative effectiveness of histamine-2 receptor antagonists as short-term therapy for gastro-esophageal reflux disease: a network meta-analysis.
Zhao F; Wang S; Liu L; Wang Y
Int J Clin Pharmacol Ther; 2016 Oct; 54(10):761-70. PubMed ID: 27443665
[TBL] [Abstract][Full Text] [Related]
56. Randomized comparative study of omeprazole and famotidine in reflux esophagitis.
Kawano S; Murata H; Tsuji S; Kubo M; Tatsuta M; Iishi H; Kanda T; Sato T; Yoshihara H; Masuda E; Noguchi M; Kashio S; Ikeda M; Kaneko A
J Gastroenterol Hepatol; 2002 Sep; 17(9):955-9. PubMed ID: 12167115
[TBL] [Abstract][Full Text] [Related]
57. Famotidine 40mg B.I.D. in the treatment of reflux oesophagitis.
Ahmed W; Qureshi H; Alam SE; Zuberi SJ
J Pak Med Assoc; 1995 Sep; 45(9):241-3. PubMed ID: 8683830
[TBL] [Abstract][Full Text] [Related]
58. [The effect of H2-receptor blockers (cimetidine and ranitidin) on parotid gland secretion and salivary carbonic anhydrase activity in the rat].
Boros I; Keszler P; Szombath D; Pósch E
Fogorv Sz; 1993 Aug; 86(8):265-73. PubMed ID: 7902302
[TBL] [Abstract][Full Text] [Related]
59. Ranitidine effervescent and famotidine wafer in the relief of episodic symptoms of gastro-oesophageal reflux disease.
Engzelius JM; Solhaug JH; Knapstad LJ; Kjaersgaard P
Scand J Gastroenterol; 1997 Jun; 32(6):513-8. PubMed ID: 9200279
[TBL] [Abstract][Full Text] [Related]
60. On-demand therapy in gastroesophageal reflux disease: a comparison of the early effects of single doses of fast-dissolving famotidine wafers and ranitidine tablets.
Johannessen T; Kristensen P
Clin Ther; 1997; 19(1):73-81. PubMed ID: 9083710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
